Hypomethylating Agents and Venetoclax for Acute Myeloid Leukemia Relapsed After Hematopoietic Stem Cell Transplant

CONCLUSION: These data support the efficacy of this combination in the alloHCT relapse setting where we report responses among nearly half of patients, with possibly greater benefit for NPM1 and IDH 1/2-mutated cases. These responses can be durable and profound as evidenced by conversion to MRD negativity.PMID:38429222 | DOI:10.1016/j.clml.2024.02.005

Source: Clinical Lymphoma and Myeloma - March 1, 2024 Category: Cancer & Oncology Authors: Filip Ionescu Jerel C David Apoorva Ravichandran David A Sallman Kendra Sweet Rami S Komrokji Onyee Chan Andrew Kuykendall Eric Padron Rawan Faramand Nelli Bejanyan Farhad Khimani Hany Elmariah Joseph Pidala Asmita Mishra Lia Perez Taiga Nishihori Jeffrey Source Type: research